Market Overview - The pharmaceutical commercial sector experienced a decline of 2.19% on January 15, with Huaren Health leading the drop [1] - The Shanghai Composite Index closed at 4112.6, down 0.33%, while the Shenzhen Component Index closed at 14306.73, up 0.41% [1] Individual Stock Performance - Notable gainers included: - RunDa Medical (603108) with a closing price of 20.04, up 1.83% and a trading volume of 700,800 shares [1] - LiuYao Group (603368) closed at 18.58, up 0.60% with a trading volume of 79,700 shares [1] - LaoBaiXing (603883) closed at 16.11, up 0.50% with a trading volume of 226,200 shares [1] - Significant decliners included: - Huaren Health (301408) closed at 23.81, down 19.99% with a trading volume of 491,100 shares [2] - ShangYu PingMin (301017) closed at 18.50, down 13.75% with a trading volume of 373,900 shares [2] - YaoYiGou (300937) closed at 37.40, down 11.79% with a trading volume of 121,400 shares [2] Capital Flow Analysis - The pharmaceutical commercial sector saw a net outflow of 990 million yuan from institutional investors, while retail investors had a net inflow of 977 million yuan [2] - The table of capital flow indicates that: - LaoBaiXing (603883) had a net inflow of 46.10 million yuan from institutional investors [3] - JiuZhouTong (600998) had a net inflow of 40.43 million yuan from institutional investors [3] - RunDa Medical (603108) had a net inflow of 37.80 million yuan from institutional investors [3]

（编辑 任世碧） 证券日报网讯 1月14日，海王生物发布公告称，公司股票价格于2026年1月13日至2026年1月14日连续两 个交易日收盘价格涨幅偏离值累计超过20%，属于股票交易异常波动的情况。经核实，公司前期披露的 信息不存在需要更正、补充之处；公司未发现近期公共媒体报道了可能或已经对公司股票交易价格产生 较大影响的未公开重大信息；近期公司生产经营情况正常，公司经营情况及内外部经营环境未发生重大 变化。 ...

证券代码：000078 证券简称：海王生物 公告编号：2026-003 深圳市海王生物工程股份有限公司 针对公司股票异常波动，经公司对有关事项核查，并向公司控股股东及实际 控制人发函核实，现将有关情况说明如下： 1、公司前期披露的信息不存在需要更正、补充之处。 2、公司未发现近期公共媒体报道了可能或已经对公司股票交易价格产生较 大影响的未公开重大信息。 3、近期公司生产经营情况正常，公司经营情况及内外部经营环境未发生重 大变化。 4、公司、控股股东和实际控制人不存在关于公司的应披露而未披露的重大 事项，或处于筹划阶段的重大事项。 5、在公司股票异常波动期间，公司控股股东、实际控制人及其一致行动人 不存在买卖公司股票的情况。 关于股票交易异常波动的公告 本公司及董事局全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 一、股票交易异常波动的情况介绍 深圳市海王生物工程股份有限公司（以下简称"公司"或"本公司"）股票 价格于2026年1月13日至2026年1月14日连续两个交易日收盘价格涨幅偏离值累 计超过20%，根据《深圳证券交易所交易规则》的相关规定，属于股票交易异常 波动的情 ...

Group 1 - The core point of the article is that Haiwang Biological has experienced a consecutive two-day trading limit increase, indicating strong market interest and speculative trading activity [1] - The stock reached a trading limit at 14:46 today, with a transaction volume of 2.977 billion yuan and a turnover rate of 26.61% [1] - The recent surge in the stock price is attributed to thematic speculation, leading to increased attention from market funds [1]

Market Overview - The Shanghai Composite Index fell by 0.64% on January 13, with six industries experiencing gains, led by the oil and petrochemical sector (up 1.62%) and the pharmaceutical and biotechnology sector (up 1.21%) [1] - The defense and military industry and the electronics sector saw the largest declines, down 5.50% and 3.30% respectively [1] Capital Flow Analysis - The net outflow of capital from the two markets was 162.743 billion yuan, with only four industries seeing net inflows [1] - The pharmaceutical and biotechnology sector had the highest net inflow of capital at 4.348 billion yuan, followed by the oil and petrochemical sector with a net inflow of 586 million yuan [1] - The electronics industry experienced the largest net outflow, totaling 37.010 billion yuan, followed by the computer industry with a net outflow of 23.107 billion yuan [1] Pharmaceutical and Biotechnology Sector Performance - The pharmaceutical and biotechnology sector rose by 1.21%, with a total of 478 stocks in the sector, of which 329 stocks increased in value and 16 stocks hit the daily limit [2] - A total of 256 stocks in the sector saw net capital inflows, with 21 stocks receiving over 100 million yuan in net inflows; leading was Mindray Medical with a net inflow of 372 million yuan [2] - The stocks with the highest net outflows included Hainan Haiyao, Huahai Pharmaceutical, and Sanbo Brain Science, with net outflows of 204 million yuan, 164 million yuan, and 153 million yuan respectively [2] Top Gainers in Pharmaceutical Sector - Notable gainers included: - Mindray Medical: up 0.09% with a capital flow of 371.57 million yuan [3] - International Medical: up 9.96% with a capital flow of 290.33 million yuan [3] - Haiwang Biological: up 9.97% with a capital flow of 242.73 million yuan [3] - Boji Pharmaceutical: up 19.96% with a capital flow of 241.23 million yuan [3] - Erkang Pharmaceutical: up 19.95% with a capital flow of 237.43 million yuan [3] Top Losers in Pharmaceutical Sector - Notable losers included: - Hainan Haiyao: down 4.82% with a capital outflow of 203.78 million yuan [5] - Huahai Pharmaceutical: down 3.60% with a capital outflow of 163.67 million yuan [5] - Sanbo Brain Science: down 3.93% with a capital outflow of 153.22 million yuan [5] - Xiangrikui: down 5.49% with a capital outflow of 147.26 million yuan [5] - Luyan Pharmaceutical: down 3.74% with a capital outflow of 110.10 million yuan [5]

证券之星消息，1月13日医药商业板块较上一交易日上涨1.21%，漱玉平民领涨。当日上证指数报收于 4138.76，下跌0.64%。深证成指报收于14169.4，下跌1.37%。医药商业板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 301017 | 漱玉平民 | 19.43 | 10.15% | 54.42万 | | 10.29 乙 | | 002589 | 瑞康医药 | 3.83 | 10.06% | 249.39万 | | 9.08亿 | | 000078 | 海王生物 | 4.08 | 9.97% | 279.00万 | | 10.88 Z | | 301408 | 华人健康 | 24.80 | 7.83% | 60.58万 | | 15.16亿 | | 301584 | 建发致新 | 32.75 | 5.58% | 15.72万 | | 5.08亿 | | 300937 | 药易购 | 40.41 | 5.18% | 18.39万 | | 7.49亿 ...

Market Overview - The pharmaceutical commercial sector increased by 0.79% compared to the previous trading day, with Luyuan Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 4082.98, down 0.07%, while the Shenzhen Component Index closed at 13959.48, down 0.51% [1] Top Gainers in Pharmaceutical Sector - Luyuan Pharmaceutical (002788) closed at 27.49, up 10.00% with a trading volume of 812,100 shares and a transaction value of 2.156 billion [1] - Saili Medical (603716) closed at 26.66, up 9.98% with a trading volume of 700,200 shares and a transaction value of 1.802 billion [1] - Dajia Weikang (301126) closed at 13.50, up 5.47% with a trading volume of 184,200 shares and a transaction value of 245 million [1] Other Notable Stocks - Run Da Medical (603108) closed at 16.31, up 5.23% with a trading volume of 378,400 shares and a transaction value of 614 million [1] - Huaren Health (301408) closed at 20.16, up 3.38% with a trading volume of 503,400 shares and a transaction value of 1.016 billion [1] Market Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 94.4079 million from institutional investors, while retail investors saw a net inflow of 213 million [2] - The overall market showed a mixed trend with some stocks experiencing significant outflows from institutional and speculative funds [2] Individual Stock Fund Flow - Saili Medical (603716) had a net inflow of 304 million from institutional investors, but a net outflow of 108 million from speculative funds [3] - Run Da Medical (603108) saw a net inflow of 62.5499 million from institutional investors, while experiencing outflows from both speculative and retail investors [3] - Huaren Health (301408) had a net inflow of 41.8956 million from institutional investors, but a significant outflow of 64.016 million from retail investors [3]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：000078 证券简称：海王生物 公告编号：2026-002 深圳市海王生物工程股份有限公司关于对外担保进展暨解除对外担保的公告 截至目前，上述不动产过户手续均办理完成。根据担保协议，控股子公司安徽皖南对安徽谷欣的担保义 务均已完全解除，安徽皖南对其债务均已不存在任何形式的担保。 三、其他说明 截至目前，本公司累计担保余额约为人民币45.09亿元（均为对子公司担保）， 约占公司2024年度经审计合并报表净资产的比例为158.55%，不存在逾期担保的情况。 一、担保情况概述 深圳市海王生物工程股份有限公司（以下简称"公司"或"本公司"）于2025年12月22日召开的第十届董事 局第四次会议审议通过了《关于控股子公司为资产转让事项提供担保的议案》。 公司控股子公司安徽海王皖南医药有限公司（以下简称"安徽皖南"）与交易对方安徽谷欣食品科技有限 公司（以下简称"安徽谷欣"）签订《资产转让协议》，将安徽皖南名下土地使用权、地上房屋及附属设 施（以下简称 "不动产"）转让给安徽谷欣。为保障交易流程顺利开展，根据宣城皖南农村商业银行股 份有限公司文鼎支行的要求，安 ...

本公司及董事局全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 一、担保情况概述 证券代码：000078 证券简称：海王生物 公告编号：2026-002 深圳市海王生物工程股份有限公司 关于对外担保进展暨解除对外担保的公告 深圳市海王生物工程股份有限公司（以下简称"公司"或"本公司"）于2025年 12月22日召开的第十届董事局第四次会议审议通过了《关于控股子公司为资产转 让事项提供担保的议案》。 三、其他说明 截至目前，本公司累计担保余额约为人民币45.09亿元（均为对子公司担保）， 约占公司2024年度经审计合并报表净资产的比例为158.55%，不存在逾期担保的 情况。 特此公告。 公司控股子公司安徽海王皖南医药有限公司（以下简称"安徽皖南"）与交 易对方安徽谷欣食品科技有限公司（以下简称"安徽谷欣"）签订《资产转让协 议》，将安徽皖南名下土地使用权、地上房屋及附属设施（以下简称 "不动产"） 转让给安徽谷欣。为保障交易流程顺利开展，根据宣城皖南农村商业银行股份有 限公司文鼎支行的要求，安徽皖南以本次转让的不动产为安徽谷欣向皖南农商银 行申请的1600万元贷款提供抵押担保 ...

Core Insights - The pharmaceutical industry is undergoing a transformation driven by policy collaboration, technological breakthroughs, and industrial restructuring, with a clear shift from price competition to value creation [1] - Shenzhen Haiwang Bioengineering Co., Ltd. is leveraging the new management team's arrival to implement asset optimization, focus on core businesses, and enhance innovation and research, marking a transition from scale expansion to quality and efficiency improvement [1] Industry Policy - The new national medical insurance drug list and the first commercial insurance innovative drug list took effect on January 1, 2026, creating a multi-tiered insurance system that opens diverse payment channels for innovative drugs [1] - The national centralized procurement has entered a new phase aimed at stabilizing clinical practices, ensuring quality, preventing collusion, and countering internal competition, guiding companies towards R&D innovation and quality enhancement [1] Management and Asset Optimization - The new management team established a strategic agenda focused on increasing sales gross margin, ensuring asset safety, improving financing channels, and optimizing capital returns, injecting strong momentum into the transformation [2] - The company is actively divesting non-core assets to enhance the operational quality and profitability of subsidiaries while reallocating limited funds to high-value areas to improve overall profitability [2] Business Focus and Innovation - Haiwang Bio is concentrating on three core sectors: pharmaceutical distribution, pharmaceutical manufacturing, and pharmaceutical R&D, driving business collaboration upgrades [3] - The pharmaceutical distribution sector showed strong performance, with medical device agency revenue reaching 4.986 billion yuan in the first half of 2025, establishing solid partnerships with industry leaders [3] - The pharmaceutical manufacturing sector has a gross margin of 36.14%, with strategies to promote production and sales collaboration [3] - R&D investment reached 31.68 million yuan in the first three quarters of 2025, with ongoing clinical trials for innovative drugs and expansion into traditional Chinese medicine and specialized food sectors [3] Governance Upgrade - The company has revised internal management systems to enhance governance transparency and decision-making efficiency, strengthening internal controls and shareholder return systems [3] - The management team has committed to focusing on high-efficiency business development over the next three years, particularly in the medical device and pharmaceutical manufacturing sectors [3] Industry Outlook - Industry experts note that Haiwang Bio's deep transformation aligns with the demands for high-quality development, showcasing determination and strength through asset optimization, business focus, innovation, and governance upgrades [4] - With the dual drivers of policy benefits and strategic focus, Haiwang Bio is expected to transition from a traditional pharmaceutical company to a technology-driven healthcare service provider, reconstructing its competitive edge [4]